缺血修饰白蛋白研究进展及临床应用  

Research Progress and Clinical Application of Ischemia Modified Albumin

作　　者：潘云芳[1] 张厚亮[1] 

机构地区：[1]静海县医院免疫科,天津301600

出　　处：《医学综述》2008年第10期1444-1446,共3页Medical Recapitulate

基　　金：天津市卫生局科研基金资助项目(04KJ64)

摘　　要：缺血修饰白蛋白(IMA)是美国食品与药物管理局批准的第一个心肌缺血生化标志物,IMA可对急性心肌缺血做出早期诊断,且明显提高对急性冠状动脉综合征早期诊断敏感性。目前,我国在该领域的研究尚处于起步阶段,对IMA检验方法的评价及改进、国人参考值范围的确立,以及在心脏损伤中应用的评价还有待进一步研究。Ischemia modified albumin is the first biochemical marker of myocardial ischemia approved by FDA. IMA may make an early diagnosis of acute coronary ischemia,and will improve the early diagnostic sensitivity of acute comary syndrome significantly. At present our country is at the start stage in this domain research. Many questions need further studying, such as the evaluation and promotion of detective method of IMA the establishment of reference value for Chinese,and the applicational evaluation in heart injury,

关 键 词：缺血修饰白蛋白 急性冠状动脉综合征 生化标志物 

分 类 号：R541.4[医药卫生—心血管疾病] R981.1[医药卫生—内科学]